Msd Sub Merck Company Profile

What is the competitive landscape for MSD SUB MERCK

MSD SUB MERCK has fourteen approved drugs.

There are seventeen US patents protecting MSD SUB MERCK drugs.

Summary for Msd Sub Merck

US Patents:	17
Tradenames:	13
Ingredients:	11
NDAs:	14

Drugs and US Patents for Msd Sub Merck

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-001	Dec 19, 2017		RX	Yes	No	8,080,580		Y	Y
Msd Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-002	Dec 15, 2015	AP	RX	Yes	Yes
Msd Sub Merck	ZEPATIER	elbasvir; grazoprevir	TABLET;ORAL	208261-001	Jan 28, 2016		DISCN	Yes	No	8,871,759		Y	Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007	AB	RX	Yes	No	8,414,921*PED				Y
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-003	Dec 19, 2017		RX	Yes	No	9,308,204		Y

Expired US Patents for Msd Sub Merck

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012	6,303,661
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012	7,459,428
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017	7,078,381
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017	7,078,381
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017	7,459,428

Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	0.75 mg/mL, 100 mL vial		2009-06-05
	Tablets	400 mg		2011-10-12
	Extended-release Capsules	50 mg/500 mg and 50 mg/1000 mg		2012-03-16
	Tablets	50 mg/500 mg and 50 mg/1000 mg		2010-10-18
	Injection	2 mg/mL, 100 mL vial		2008-12-18
	Injection	1 g/vial		2013-06-20
	Ophthalmic Solution	2%		2005-10-11
	Extended-release Tablets	100 mg/1000 mg		2012-10-22
	Injection	2 mg/mL, 10 mL vial		2008-09-30

International Patents for Msd Sub Merck Drugs

Country	Patent Number	Estimated Expiration
Malaysia	169311
Spain	2375788
Argentina	026605
Portugal	1259550
Israel	172563

Supplementary Protection Certificates for Msd Sub Merck Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1441735	SZ 30/2008	Austria		PRODUCT NAME: RALTEGRAVIR ODER DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE DAS KALIUMSALZ
1261586	15/2012	Austria		PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124
2310095	C02310095/01	Switzerland		PRODUCT NAME: GRAZOPREVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65861 01.04.2016
1441735	PA2008007	Lithuania		PRODUCT NAME: RALTEGRAVIRUM; REG. NO/DATE: EU/1/07/436/001-002 20071220
2310095	CA 2016 00070	Denmark		PRODUCT NAME: GRAZOPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Msd Merck Co
• Msd Sub Merck